Context Therapeutics Inc. 8-K

What Happened Context Therapeutics announced that on March 11, 2026 the Delaware Court of Chancery approved a stipulated judgment and the company filed a Certificate of Correction removing two charter provisions that created three‑year staggered director terms and limited director removal to “for cause.” The company said the stockholder action filed Feb. 4, 2026 by the Vladimir Gusinsky Revocable Trust was dismissed with prejudice as to the plaintiff (the court retains jurisdiction over any mootness fee application). As a result, current directors’ terms will expire at the company’s 2026 annual meeting (scheduled for June 24, 2026, record date April 27, 2026), and directors may now be removed, with or without cause, by a majority of shares entitled to vote.

Key Details

• Delaware Court approved the Stipulated Judgment and Context filed a Certificate of Correction on March 11, 2026.
• Charter provisions invalidated: Article V, Section 2 (three‑year director terms) and Article VI, Section 1 (removal only for cause).
• 2026 Annual Meeting: scheduled June 24, 2026; record date April 27, 2026. Company plans to propose director elections for one‑year terms.
• Stockholder deadlines: advance notice under the Bylaws — March 14, 2026 by 5:00 p.m. EDT; universal proxy (Rule 14a‑19) information deadline — April 13, 2026.

Why It Matters This filing changes Context’s governance structure from staggered multi‑year board terms to annual elections and allows shareholders greater ability to remove directors. For investors, that raises the potential for more frequent board turnover and makes proxy contests or director challenges easier to pursue. The settlement also removes a pending legal uncertainty (action dismissed with prejudice), though a fee application could still be addressed by the court. Investors who want to nominate directors or submit proposals need to meet the stated March 14 and April 13, 2026 deadlines to participate in the upcoming annual meeting.